ArticleHIV/AIDS (Auckland, N.Z.)2025
Hypothetical Preferences and Concerns for Long-Acting Injectable HIV PrEP Use Among Female Barmaids in Ubungo, Dar Es Salaam, Tanzania.
Article in HIV/AIDS (Auckland, N.Z.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Oral HIV pre-exposure prophylaxis (PrEP) has been introduced globally, but women in sub-Saharan Africa frequently experience challenges in uptake and adherence. Female barmaids are at HIV risk due to transactional sex. However, uptake and adherence to oral PrEP pills is poor. Long-acting injectable (LAI) PrEP has the potential to increase prevention by improving adherence. Nevertheless, LAI PrEP is yet to be initiated in Tanzania. We explored preferences and concerns about LAI PrEP use among female barmaids in Ubungo municipality. Methods: We conducted in-depth interviews with 17 purposefully selected female barmaids. Interviews were conducted using a guide with semi-structured questions. We adopted an inductive approach for analyzing data. Findings: The majority of PrEP non-users expressed no preference for any form of PrEP, while oral PrEP-users preferred LAI PrEP. Overall, LAI PrEP was preferred due to its discretion, fewer side effects, prolonged prevention, and reduced fatigue compared to oral pill PrEP with concerns about large pill size, side effects, and the burden of daily use. Most interviewees indicated a three-month PrEP injection preference, though some preferred a monthly PrEP injection for effective monitoring and control of potential side effects. Regarding the delivery model, the healthcare facility was mostly preferred for timely services, convenience more privacy and reduced stigma. Community spots were preferred for convenience and friendlier services from providers. The majority reported no major concerns about using LAI PrEP, though a few expressed concerns about its trial phase, potential links to cancer, risky sexual behaviours, and side effects such as fatigue, dizziness. Conclusion: The majority of the interviewees expressed strong interest in LAI PrEP and reported fewer concerns, emphasizing more convenience and discretion. Our findings suggest that since LAI can address challenges of adherence associated with daily PrEP pills, it is important to introduce it to expand HIV prevention options for barmaids and other women at risk of HIV in Tanzania.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.